Top Page
Q-linea AB
(QLINEA)
Q-linea AB (QLINEA) vs. iShares MSCI Sweden ETF (EWD)
Q-linea AB Business Overview & Revenue Model
Q-linea AB Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.39M | 2.36M | 4.44M | 12.79M | 9.34M | 243.00K |
| Gross Profit | -49.07M | -11.11M | 995.00K | -21.38M | -25.03M | -32.02M |
| EBITDA | -167.24M | -195.40M | -210.99M | -252.69M | -218.48M | -211.02M |
| Net Income | -188.37M | -216.87M | -229.37M | -275.77M | -233.18M | -220.19M |
Balance Sheet | ||||||
| Total Assets | 155.38M | 147.99M | 231.98M | 207.39M | 466.63M | 412.23M |
| Cash, Cash Equivalents and Short-Term Investments | 42.58M | 25.66M | 81.89M | 72.62M | 166.03M | 306.89M |
| Total Debt | 47.86M | 151.21M | 20.56M | 20.93M | 79.00K | 331.00K |
| Total Liabilities | 67.93M | 175.45M | 42.34M | 45.76M | 35.84M | 32.03M |
| Stockholders Equity | 87.45M | -27.46M | 189.64M | 161.63M | 430.79M | 380.20M |
Cash Flow | ||||||
| Free Cash Flow | -171.35M | -187.49M | -236.86M | -268.11M | -267.02M | -250.53M |
| Operating Cash Flow | -163.79M | -182.50M | -228.52M | -250.86M | -255.05M | -237.31M |
| Investing Cash Flow | -6.56M | -5.04M | -7.77M | 315.25M | -23.82M | -32.30M |
| Financing Cash Flow | 205.60M | 131.27M | 245.41M | -6.60M | 283.81M | 253.78M |
Q-linea AB Technical Analysis
Q-linea AB Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | kr3.12B | -6.02 | -71.87% | ― | -91.85% | -6.65% | |
41 Neutral | kr566.28M | -0.40 | -35.70% | ― | -18.46% | 4.90% | |
41 Neutral | kr96.58M | -0.62 | -72.82% | ― | 40.91% | 57.92% | |
40 Underperform | kr416.36M | -0.24 | -330.10% | ― | 270.64% | 62.29% | |
36 Underperform | kr203.66M | -2.53 | -51.35% | ― | ― | -34.02% | |
32 Underperform | kr28.23M | -0.18 | -199.25% | ― | ― | 0.30% |
Q-linea AB Corporate Events
Q-linea AB has increased its total number of shares and votes to 18,949,081 as of November 28, 2025, following a rights issue and a directed issue of shares. This expansion in share capital is a strategic move to strengthen the company’s financial position, potentially enhancing its market presence and operational capabilities in the healthcare sector.
Q-linea AB has announced a reorganization and changes in its executive leadership team, aiming to enhance its commercial focus and operational efficiency. The restructuring includes a reduction of 16 employees in Sweden, with no impact on operations in the US and Italy, and the appointment of Ylva Molin to the Executive Management Group as Manager of Assay Development, while Jonas Melin transitions to a Senior Technical Advisor role and CFO Christer Samuelsson plans to depart.
Q-linea AB has submitted a 510(k) application to the FDA for expanded organism and antimicrobial claims on their ASTar BC G- panel, enhancing its clinical utility for treating bacteremia and sepsis. This move follows a successful clinical trial and aims to align the FDA-cleared panel with its EU counterpart, potentially increasing its adoption in the US market, with a second FDA clearance expected by spring 2026.
Q-linea AB, a company listed on Nasdaq Stockholm, has resolved to issue 16,800 shares as guarantee compensation to Wellsford Limited, deviating from shareholders’ preferential rights. This decision follows a successful capital raising effort and aims to complete the preferential rights issue, benefiting the company and its shareholders by increasing the share capital and ensuring financial stability.
Q-linea AB announced the outcome of its rights issue, which was subscribed to 97.1 percent, raising approximately SEK 312 million before transaction costs. This capital increase will significantly enhance Q-linea’s financial position, potentially impacting its market operations and stakeholder interests, especially considering the dilution effect of approximately 66 percent.
Q-linea AB, listed on Nasdaq Stockholm, has published a prospectus for its upcoming rights issue, which was approved by its board and an extraordinary general meeting. The rights issue aims to strengthen the company’s financial position, with Handelsbanken and Advokatfirman Lindahl serving as financial and legal advisors, respectively. The prospectus is available on Q-linea’s and the Swedish Financial Supervisory Authority’s websites.
Q-linea has announced a cost efficiency program aimed at reallocating resources from development to market-facing roles, particularly in the US, while reducing operational costs by 10% from Q3 2025 levels. This strategic move follows the completion of major development projects and aims to enhance profitability and achieve breakeven by 2027. The company will consolidate its Swedish offices and continue to focus on expanding its ASTar testing menu, which is expected to drive sales growth.
Q-linea AB held an extraordinary general meeting where shareholders approved a resolution to issue new shares with preferential rights for existing shareholders, increasing the company’s share capital significantly. This move is aimed at strengthening the company’s financial position and supporting its growth strategy. Additionally, amendments to the articles of association were made to accommodate the new share structure, and the board was authorized to issue shares to guarantors of the rights issue, reflecting strategic financial maneuvers to ensure the company’s robust market positioning.
Q-linea AB’s Q3 2025 report highlights significant growth in their ASTar platform, with new contracts in the US, Italy, and Saudi Arabia, and increased demand for consumables. The company’s strategic partnerships with pharmaceutical firms aim to expand the ASTar menu, while internalizing consumable production reduces costs. Despite a setback in the ESTAR tender appeal, Q-linea’s pipeline is robust, driven by the discontinuation of the Pheno platform by a competitor. A rights issue of SEK 322 million is set to support their goal of breakeven by 2027, as they continue to focus on customer-centric and cost-efficient operations.
Q-linea AB has announced the appointment of Stuart Gander as the new CEO, with Anders Ljunggren transitioning to the role of deputy CEO. This leadership change is seen as a natural progression, given Gander’s prior role as president of the Q-linea group and his recent residency in Sweden, which aligns with the company’s strategic goals and operational continuity.
Q-linea AB has announced that a prominent US level 1 University Hospital Trauma Center has adopted its ASTar system for routine clinical use, following a successful evaluation period. This adoption highlights the system’s advantages, such as full automation, high throughput, and a broad antibiotic panel, positioning Q-linea for further growth in the healthcare sector.
Q-linea AB has announced a rights issue to raise approximately SEK 322 million, with strong support from existing shareholders and commitments covering about 85.6% of the issue. This funding aims to help the company reach break-even by 2027, accelerate commercialization, and strengthen its market position, particularly in the US market, where it anticipates significant growth.
Q-linea AB announced a strategic update, emphasizing its goal to contract 30-40 ASTar units by 2025, with expectations to exceed 200 units by 2027. Despite a setback in the ESTAR tender in Italy, the company is expanding its market presence across Europe and the US, with significant cost reductions achieved through in-house production and a SEK 322 million rights issue to support its path to breakeven by 2027.
Q-linea AB has announced an extraordinary general meeting to discuss a new issue of shares with preferential rights for existing shareholders. The meeting will address the board’s resolution to increase the company’s share capital by issuing new shares, which aims to strengthen the company’s financial position and potentially enhance shareholder value.
Q-linea AB announced that the Italian Supreme Administrative Court has overturned a previous ruling in their favor regarding the ESTAR tender for rapid AST. Although the tender, valued at EUR 1.7 million over five years, is not yet formally awarded, Q-linea assesses its chances of winning as low. Despite this setback, the company maintains a positive outlook on the Italian market.